Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies

Molecular Therapy

Volumn 25, Issue 2, 2017, Pages 523-533

  Dheilly, Elie ^a   Moine, Valéry ^a   Broyer, Lucile ^a   Salgado Pires, Susana ^a   Johnson, Zoë ^a   Papaioannou, Anne ^a   Cons, Laura ^a   Calloud, Sébastien ^a   Majocchi, Stefano ^a   Nelson, Robert ^a   Rousseau, François ^a   Ferlin, Walter ^a   Kosco Vilbois, Marie ^a   Fischer, Nicolas ^a   Masternak, Krzysztof ^a  

^a NONE   (Switzerland)

Author keywords

bispecific antibody; cancer immunotherapy; CD19; CD47; immune checkpoint; macrophage; mesothelin; phagocytosis; pharmacokinetics

Indexed keywords

BISPECIFIC ANTIBODY; CD19 ANTIGEN; CD47 ANTIGEN; CD47 CD19 BISPECIFIC ANTIBODY; IMMUNOGLOBULIN G1; MEMBRANE PROTEIN; MESOTHELIN; SIGNAL REGULATORY PROTEIN ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN BINDING; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SINK; ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CANCER CELL; CELL KILLING; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PHAGOCYTOSIS; PROTEIN PROTEIN INTERACTION; SINGLE DRUG DOSE; TREATMENT DURATION; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; DISEASE MODEL; DRUG SCREENING; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONOBESE DIABETIC MOUSE; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CD47 ANTIGEN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHAGOCYTOSIS; PROTEIN BINDING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85016301779     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2016.11.006     Document Type: Article

References (64)

1. 1 Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
2. 2 Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
3. 3 Palucka, A.K., Coussens, L.M., The Basis of Oncoimmunology. Cell 164 (2016), 1233–1247.
4. 4 Melero, I., Berman, D.M., Aznar, M.A., Korman, A.J., Pérez Gracia, J.L., Haanen, J., Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15 (2015), 457–472.
5. 5 Mills, C.D., Lenz, L.L., Harris, R.A., A Breakthrough: Macrophage-Directed Cancer Immunotherapy. Cancer Res. 76 (2016), 513–516.
6. 6 Weiskopf, K., Weissman, I.L., Macrophages are critical effectors of antibody therapies for cancer. MAbs 7 (2015), 303–310.
7. 7 Oldenborg, P.A., Zheleznyak, A., Fang, Y.F., Lagenaur, C.F., Gresham, H.D., Lindberg, F.P., Role of CD47 as a marker of self on red blood cells. Science 288 (2000), 2051–2054.
8. 8 Brown, E.J., Frazier, W.A., Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 11 (2001), 130–135.
9. 9 Jaiswal, S., Jamieson, C.H., Pang, W.W., Park, C.Y., Chao, M.P., Majeti, R., Traver, D., van Rooijen, N., Weissman, I.L., CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138 (2009), 271–285.
10. 10 Majeti, R., Chao, M.P., Alizadeh, A.A., Pang, W.W., Jaiswal, S., Gibbs, K.D. Jr., van Rooijen, N., Weissman, I.L., CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138 (2009), 286–299.
11. 11 Tsai, R.K., Discher, D.E., Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J. Cell Biol. 180 (2008), 989–1003.
12. 12 Oldenborg, P.A., Gresham, H.D., Lindberg, F.P., CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J. Exp. Med. 193 (2001), 855–862.
13. 13 Gardai, S.J., McPhillips, K.A., Frasch, S.C., Janssen, W.J., Starefeldt, A., Murphy-Ullrich, J.E., Bratton, D.L., Oldenborg, P.A., Michalak, M., Henson, P.M., Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123 (2005), 321–334.
14. 14 Chao, M.P., Weissman, I.L., Majeti, R., The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol. 24 (2012), 225–232.
15. 15 Baccelli, I., Stenzinger, A., Vogel, V., Pfitzner, B.M., Klein, C., Wallwiener, M., Scharpff, M., Saini, M., Holland-Letz, T., Sinn, H.P., et al. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget 5 (2014), 8147–8160.
16. 16 Baccelli, I., Schneeweiss, A., Riethdorf, S., Stenzinger, A., Schillert, A., Vogel, V., Klein, C., Saini, M., Bäuerle, T., Wallwiener, M., et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 31 (2013), 539–544.
17. 17 Chan, K.S., Espinosa, I., Chao, M., Wong, D., Ailles, L., Diehn, M., Gill, H., Presti, J. Jr., Chang, H.Y., van de Rijn, M., et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. USA 106 (2009), 14016–14021.
18. 18 Cioffi, M., Trabulo, S., Hidalgo, M., Costello, E., Greenhalf, W., Erkan, M., Kleeff, J., Sainz, B. Jr., Heeschen, C., Inhibition of CD47 effectively targets pancreatic cancer stem cells via dual mechanisms. Clin. Cancer Res. 21 (2015), 2325–2337.
19. 19 Lee, T.K., Cheung, V.C., Lu, P., Lau, E.Y., Ma, S., Tang, K.H., Tong, M., Lo, J., Ng, I.O., Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 60 (2014), 179–191.
20. 20 Willingham, S.B., Volkmer, J.P., Gentles, A.J., Sahoo, D., Dalerba, P., Mitra, S.S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J.D., et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. USA 109 (2012), 6662–6667.
21. 21 Chao, M.P., Alizadeh, A.A., Tang, C., Myklebust, J.H., Varghese, B., Gill, S., Jan, M., Cha, A.C., Chan, C.K., Tan, B.T., et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142 (2010), 699–713.
22. 22 Wang, H., Tan, M., Zhang, S., Li, X., Gao, J., Zhang, D., Hao, Y., Gao, S., Liu, J., Lin, B., Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma. Int. J. Mol. Sci. 16 (2015), 3391–3404.
23. 23 Xiao, Z., Chung, H., Banan, B., Manning, P.T., Ott, K.C., Lin, S., Capoccia, B.J., Subramanian, V., Hiebsch, R.R., Upadhya, G.A., et al. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett. 360 (2015), 302–309.
24. 24 Yoshida, K., Tsujimoto, H., Matsumura, K., Kinoshita, M., Takahata, R., Matsumoto, Y., Hiraki, S., Ono, S., Seki, S., Yamamoto, J., Hase, K., CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med. 4 (2015), 1322–1333.
25. 25 Weiskopf, K., Ring, A.M., Ho, C.C., Volkmer, J.P., Levin, A.M., Volkmer, A.K., Ozkan, E., Fernhoff, N.B., van de Rijn, M., Weissman, I.L., Garcia, K.C., Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341 (2013), 88–91.
26. 26 Zhao, X.W., van Beek, E.M., Schornagel, K., Van der Maaden, H., Van Houdt, M., Otten, M.A., Finetti, P., Van Egmond, M., Matozaki, T., Kraal, G., et al. CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc. Natl. Acad. Sci. USA 108 (2011), 18342–18347.
27. 27 Edris, B., Weiskopf, K., Volkmer, A.K., Volkmer, J.P., Willingham, S.B., Contreras-Trujillo, H., Liu, J., Majeti, R., West, R.B., Fletcher, J.A., et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc. Natl. Acad. Sci. USA 109 (2012), 6656–6661.
28. 28 Lo, J., Lau, E.Y., So, F.T., Lu, P., Chan, V.S., Cheung, V.C., Ching, R.H., Cheng, B.Y., Ma, M.K., Ng, I.O., Lee, T.K., Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. Liver Int. 36 (2016), 737–745.
29. 29 Sagawa, M., Shimizu, T., Fukushima, N., Kinoshita, Y., Ohizumi, I., Uno, S., Kikuchi, Y., Ikeda, Y., Yamada-Okabe, H., Kizaki, M., A new disulfide-linked dimer of a single-chain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells via the hypoxia inducible factor-1α pathway. Cancer Sci. 102 (2011), 1208–1215.
30. 30 Uno, S., Kinoshita, Y., Azuma, Y., Tsunenari, T., Yoshimura, Y., Iida, S., Kikuchi, Y., Yamada-Okabe, H., Fukushima, N., Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia. Oncol. Rep. 17 (2007), 1189–1194.
31. 31 Mateo, V., Lagneaux, L., Bron, D., Biron, G., Armant, M., Delespesse, G., Sarfati, M., CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nat. Med. 5 (1999), 1277–1284.
32. 32 Zhang, H., Lu, H., Xiang, L., Bullen, J.W., Zhang, C., Samanta, D., Gilkes, D.M., He, J., Semenza, G.L., HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc. Natl. Acad. Sci. USA 112 (2015), E6215–E6223.
33. 33 Kaur, S., Elkahloun, A.G., Singh, S.P., Chen, Q.R., Meerzaman, D.M., Song, T., Manu, N., Wu, W., Mannan, P., Garfield, S.H., Roberts, D.D., A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer. Oncotarget 7 (2016), 10133–10152.
34. 34 Soto-Pantoja, D.R., Terabe, M., Ghosh, A., Ridnour, L.A., DeGraff, W.G., Wink, D.A., Berzofsky, J.A., Roberts, D.D., CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res. 74 (2014), 6771–6783.
35. 35 Liu, X., Pu, Y., Cron, K., Deng, L., Kline, J., Frazier, W.A., Xu, H., Peng, H., Fu, Y.X., Xu, M.M., CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21 (2015), 1209–1215.
36. 36 Wang, Y., Xu, Z., Guo, S., Zhang, L., Sharma, A., Robertson, G.P., Huang, L., Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol. Ther. 21 (2013), 1919–1929.
37. 37 Sockolosky, J.T., Dougan, M., Ingram, J.R., Ho, C.C., Kauke, M.J., Almo, S.C., Ploegh, H.L., Garcia, K.C., Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc. Natl. Acad. Sci. USA 113 (2016), E2646–E2654.
38. 38 Tseng, D., Volkmer, J.P., Willingham, S.B., Contreras-Trujillo, H., Fathman, J.W., Fernhoff, N.B., Seita, J., Inlay, M.A., Weiskopf, K., Miyanishi, M., Weissman, I.L., Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc. Natl. Acad. Sci. USA 110 (2013), 11103–11108.
39. 39 Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., Willingham, S., Howard, M., Prohaska, S., Volkmer, J., et al. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. PLoS ONE, 10, 2015, e0137345.
40. 40 Ho, C.C., Guo, N., Sockolosky, J.T., Ring, A.M., Weiskopf, K., Özkan, E., Mori, Y., Weissman, I.L., Garcia, K.C., “Velcro” engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis. J. Biol. Chem. 290 (2015), 12650–12663.
41. 41 Kontermann, R.E., Brinkmann, U., Bispecific antibodies. Drug Discov. Today 20 (2015), 838–847.
42. 42 Spiess, C., Zhai, Q., Carter, P.J., Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol. Immunol. 67:2 Pt A (2015), 95–106.
43. 43 Chan, A.C., Carter, P.J., Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10 (2010), 301–316.
44. 44 Kontermann, R.E., Dual targeting strategies with bispecific antibodies. MAbs 4 (2012), 182–197.
45. 45 Piccione, E.C., Juarez, S., Liu, J., Tseng, S., Ryan, C.E., Narayanan, C., Wang, L., Weiskopf, K., Majeti, R., A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs 7 (2015), 946–956.
46. 46 Piccione, E.C., Juarez, S., Tseng, S., Liu, J., Stafford, M., Narayanan, C., Wang, L., Weiskopf, K., Majeti, R., SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells. Clin. Cancer Res. 22 (2016), 5109–5119.
47. 47 Pastan, I., Hassan, R., Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 74 (2014), 2907–2912.
48. 48 Bournazos, S., Ravetch, J.V., Fcγ receptor pathways during active and passive immunization. Immunol. Rev. 268 (2015), 88–103.
49. 49 Nimmerjahn, F., Ravetch, J.V., Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8 (2008), 34–47.
50. 50 Jiang, X.R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., Schenerman, M., Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat. Rev. Drug Discov. 10 (2011), 101–111.
51. 51 Fischer, N., Elson, G., Magistrelli, G., Dheilly, E., Fouque, N., Laurendon, A., Gueneau, F., Ravn, U., Depoisier, J.F., Moine, V., et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat. Commun., 6, 2015, 6113.
52. 52 Gresham, H.D., Goodwin, J.L., Allen, P.M., Anderson, D.C., Brown, E.J., A novel member of the integrin receptor family mediates Arg-Gly-Asp-stimulated neutrophil phagocytosis. J. Cell Biol. 108 (1989), 1935–1943.
53. 53 Gül, N., van Egmond, M., Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer. Cancer Res. 75 (2015), 5008–5013.
54. 54 Leidi, M., Gotti, E., Bologna, L., Miranda, E., Rimoldi, M., Sica, A., Roncalli, M., Palumbo, G.A., Introna, M., Golay, J., M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J. Immunol. 182 (2009), 4415–4422.
55. 55 Subramanian, S., Tsai, R., Sen, S., Dahl, K.N., Discher, D.E., Membrane mobility and clustering of Integrin Associated Protein (IAP, CD47)–major differences between mouse and man and implications for signaling. Blood Cells Mol. Dis. 36 (2006), 364–372.
56. 56 Mouro-Chanteloup, I., Delaunay, J., Gane, P., Nicolas, V., Johansen, M., Brown, E.J., Peters, L.L., Van Kim, C.L., Cartron, J.P., Colin, Y., Evidence that the red cell skeleton protein 4.2 interacts with the Rh membrane complex member CD47. Blood 101 (2003), 338–344.
57. 57 Oldenborg, P.A., CD47: A Cell Surface Glycoprotein Which Regulates Multiple Functions of Hematopoietic Cells in Health and Disease. ISRN Hematol., 2013, 2013, 614619.
58. 58 Barclay, A.N., Van den Berg, T.K., The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. Annu. Rev. Immunol. 32 (2014), 25–50.
59. 59 Sick, E., Jeanne, A., Schneider, C., Dedieu, S., Takeda, K., Martiny, L., CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. Br. J. Pharmacol. 167 (2012), 1415–1430.
60. 60 Soto-Pantoja, D.R., Kaur, S., Roberts, D.D., CD47 signaling pathways controlling cellular differentiation and responses to stress. Crit. Rev. Biochem. Mol. Biol. 50 (2015), 212–230.
61. 61 Sarfati, M., Fortin, G., Raymond, M., Susin, S., CD47 in the immune response: role of thrombospondin and SIRP-alpha reverse signaling. Curr. Drug Targets 9 (2008), 842–850.
62. 62 Murata, Y., Kotani, T., Ohnishi, H., Matozaki, T., The CD47-SIRPα signalling system: its physiological roles and therapeutic application. J. Biochem. 155 (2014), 335–344.
63. 63 Matozaki, T., Murata, Y., Okazawa, H., Ohnishi, H., Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol. 19 (2009), 72–80.
64. 64 Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., Zhang, F., Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8 (2013), 2281–2308.